MaxQ Medical has raised $31.5 million in Series A funding to bring its advanced prostate cancer imaging system designed to provide urologists complete visibility of the prostate and the ability to deliver individualized treatment in a single procedure, starting with benign prostatic hyperplasia (BPH) and expanding into prostate cancer focal therapy and prostate diagnostics.
“There’s a strong need in urology for technology that allows physicians to see and treat the prostate in one setting, and we’re encouraged by MaxQ’s vision for treating prostate disease,” said Gabriela Kaynor, Chair of Olympus Innovation Ventures. Prostate cancer is the second-leading cause of cancer death among American men. An estimated 36,320 men in the United States are projected to die from the disease in 2026, according to data from the American Cancer Society.
The investment round was co-led by Atlantic Blue Ventures, S3 Ventures, and Olympus Innovation Ventures, with participation from its existing investor, Hillside Capital.
Amir Tehrani, CEO of MaxQ Medical, said: this funding lets us continue the clinical evaluations already underway and move closer to giving physicians and their patients a better option.
MaxQ Medical is developing a platform called the MaxQ System, which is investigational and is not currently available for commercial use in the United States.
The platform combines advanced imaging with tissue-selective therapy in a single transurethral procedure, giving urologists full visibility inside the prostate and the ability to treat what they see, without the anatomic limitations of approaches that work from outside of the prostate. The design is intended to preserve the urethra and minimize side effects such as injury, swelling, and bleeding, and impact on sexual functions, which remain common concerns with current treatment options.
The company’s first indication is benign prostate hyperplasia (BPH), with plans to expand into focal therapy for prostate cancer and, longer term, into broader prostate diagnostics including biopsy and tumor mapping.
MaxQ Medical competes with many advanced cancer care startups. More recently, SkinBit, a developer of an AI-driven full-body skin cancer scanning platform, raised $6 million in a pre-seed round to bring twenty-minute, full-body skin cancer scanning technology to clinics and wellness centers in the U.S.
In another deal, Inocras, a bioinformatics-led startup harnessing the power of whole-genome data and proprietary AI analytics to deliver curated insights for oncology and rare cancer diseases, has raised $31 million in an oversubscribed Series B-3 financing.